The probable dolichyl pyrophosphate Glc1Man9GlcNAc2 alpha-1,3-glucosyltransferase (ALG8) (Stanchi et al. 2001, Chantret et al. 2003) normally adds the second glucose moiety to the lipid-linked oligosaccharide precursor (LLO aka N-glycan precursor) which is required for subsequent N-glycosylation of proteins. Defects in ALG8 can cause congenital disorder of glycosylation 1h (ALG8-CDG, CDG-1h; MIM:608104), a multisystem disorder characterised by under-glycosylated serum glycoproteins (Chantret et al. 2003, Schollen et al. 2004). ALG8 deficiency is accompanied by an accumulation of the N-glycan precursor (Glc)1 (GlcNAc)2 (Man)9 (PP-Dol)1. CDG type 1 diseases result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency.
Stanchi, F, Bertocco, E, Toppo, S, Dioguardi, R, Simionati, B, Cannata, N, Zimbello, R, Lanfranchi, G, Valle, G
Chantret, I, Dancourt, J, Dupré, T, Delenda, C, Bucher, S, Vuillaumier-Barrot, S, Ogier de Baulny, H, Peletan, C, Danos, O, Seta, N, Durand, G, Oriol, R, Codogno, P, Moore, SE
Schollen, E, Frank, CG, Keldermans, L, Reyntjens, R, Grubenmann, CE, Clayton, PT, Winchester, BG, Smeitink, J, Wevers, RA, Aebi, M, Hennet, T, Matthijs, G
© 2021 Reactome
